{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,16]],"date-time":"2026-11-16T15:07:49Z","timestamp":1794841669810,"version":"4.9.1"},"reference-count":29,"publisher":"American Society of Hematology","issue":"20","content-domain":{"domain":["ashpublications.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2025,10,28]]},"abstract":"<jats:sec>\n                    <jats:title>Abstract<\/jats:title>\n                    <jats:p>Diffuse large B-cell lymphoma (DLBCL) and follicular lymphoma (FL) are highly radiosensitive with immune-driven abscopal responses reported. Programmed cell death 1\/programmed cell death ligand 1 (PD-L1) inhibitors are relatively ineffective in DLBCL\/FL; however, evidence suggests synergy with radiotherapy (RT), but no clear biomarkers. This phase 1 study examined the safety of escalating RT dose and treated volumes with durvalumab (PD-L1 inhibitor) in 34 adults with relapsed\/refractory DLBCL and relapsed\/refractory FL, and the role of immune-cell subsets on outcomes. Patients received external-beam RT (2.5-30 Gray [Gy], 5 or 10 fractions up to 3 target sites) plus durvalumab from RT day 2, until progression. Novel positron emission tomography (PET) biodistribution studies of 89Zr-durvalumab and CD8 T-cell minibody-89Zr-Df-crefmirlimab were incorporated. The RT recommended phase 2 dose was 10 Gy\/5 fractions and 30 Gy\/10 fractions to 3 sites for FL and DLBCL, respectively. The most common grade 3 to 4 toxicities included anemia (9%), neutropenia (11%), and liver dysfunction (5%). Overall response was 60% in FL (3\/5; complete response, 40% [2\/5]), and 14% in DLBCL (4\/27; complete response, 7% [2\/27]). Distinct peripheral blood and tumor T-cell features, including CD8 PET\u2013determined intratumoral CD8 T-cells, correlated with response (P &amp;lt; .05). RT-durvalumab with 30 Gy\/10 fractions of RT to 3 disease sites is safe, and offers promising responses in FL. Intratumoral and peripheral blood CD8 T-cell dysregulation correlate with treatment response. This trial was registered at www.clinicaltrials.gov as #NCT03610061.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1182\/bloodadvances.2025016505","type":"journal-article","created":{"date-parts":[[2025,6,20]],"date-time":"2025-06-20T18:00:36Z","timestamp":1750442436000},"page":"5263-5273","update-policy":"https:\/\/doi.org\/10.1182\/blood.2019cm0000","source":"Crossref","is-referenced-by-count":4,"title":["T-cell dysregulation informs radiotherapy-immunotherapy response in B-cell lymphoma: results from a phase 1 trial"],"prefix":"10.1182","volume":"9","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-0376-2559","authenticated-orcid":false,"given":"Eliza A.","family":"Hawkes","sequence":"first","affiliation":[{"name":"1Olivia Newton-John Cancer Research Institute at Austin Health, Heidelberg, Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8964-0965","authenticated-orcid":false,"given":"Jodie B.","family":"Palmer","sequence":"additional","affiliation":[{"name":"1Olivia Newton-John Cancer Research Institute at Austin Health, Heidelberg, Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7057-2747","authenticated-orcid":false,"given":"Richard","family":"Khor","sequence":"additional","affiliation":[{"name":"1Olivia Newton-John Cancer Research Institute at Austin Health, Heidelberg, Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8641-456X","authenticated-orcid":false,"given":"Sze Ting","family":"Lee","sequence":"additional","affiliation":[{"name":"1Olivia Newton-John Cancer Research Institute at Austin Health, Heidelberg, Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Melinda","family":"Burgess","sequence":"additional","affiliation":[{"name":"2Frazer Institute, The University of Queensland, Brisbane, Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0782-6951","authenticated-orcid":false,"given":"Soi C.","family":"Law","sequence":"additional","affiliation":[{"name":"3Blood Cancer Research Group, Mater Research, Translational Research Institute, Brisbane, Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1000-5393","authenticated-orcid":false,"given":"Maher K.","family":"Gandhi","sequence":"additional","affiliation":[{"name":"3Blood Cancer Research Group, Mater Research, Translational Research Institute, Brisbane, Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4006-2380","authenticated-orcid":false,"given":"Geoffrey","family":"Chong","sequence":"additional","affiliation":[{"name":"1Olivia Newton-John Cancer Research Institute at Austin Health, Heidelberg, Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3185-6488","authenticated-orcid":false,"given":"Jake","family":"Shortt","sequence":"additional","affiliation":[{"name":"4Monash Haematology, Monash Health, Clayton, Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0000-9905-9667","authenticated-orcid":false,"given":"Rakin","family":"Chowdhury","sequence":"additional","affiliation":[{"name":"2Frazer Institute, The University of Queensland, Brisbane, Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7412-3271","authenticated-orcid":false,"given":"Fiona","family":"Swain","sequence":"additional","affiliation":[{"name":"2Frazer Institute, The University of Queensland, Brisbane, Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Leonid","family":"Churilov","sequence":"additional","affiliation":[{"name":"5Faculty of Medicine, The University of Melbourne, Parkville, Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0900-5815","authenticated-orcid":false,"given":"Michael","family":"MacManus","sequence":"additional","affiliation":[{"name":"6Peter MacCallum Cancer Centre, Parkville, Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Charmaine","family":"Smith","sequence":"additional","affiliation":[{"name":"1Olivia Newton-John Cancer Research Institute at Austin Health, Heidelberg, Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0003-3190-6518","authenticated-orcid":false,"given":"Fiona E.","family":"Scott","sequence":"additional","affiliation":[{"name":"1Olivia Newton-John Cancer Research Institute at Austin Health, Heidelberg, Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0009-3094-8867","authenticated-orcid":false,"given":"Arina","family":"Martynchyk","sequence":"additional","affiliation":[{"name":"1Olivia Newton-John Cancer Research Institute at Austin Health, Heidelberg, Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1615-0540","authenticated-orcid":false,"given":"Allison","family":"Barraclough","sequence":"additional","affiliation":[{"name":"7Fiona Stanley Hospital, Perth, Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6880-2876","authenticated-orcid":false,"given":"Kate","family":"Manos","sequence":"additional","affiliation":[{"name":"8Flinders Medical Centre, Adelaide, Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6656-295X","authenticated-orcid":false,"given":"Andrew M.","family":"Scott","sequence":"additional","affiliation":[{"name":"1Olivia Newton-John Cancer Research Institute at Austin Health, Heidelberg, Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9009-9934","authenticated-orcid":false,"given":"Colm","family":"Keane","sequence":"additional","affiliation":[{"name":"2Frazer Institute, The University of Queensland, Brisbane, Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"234","published-online":{"date-parts":[[2025,10,17]]},"reference":[{"issue":"34","key":"2025102809114897500_bib1","doi-asserted-by":"crossref","first-page":"3300","DOI":"10.1200\/JCO.18.02365","article-title":"Progression of disease within 24 months in follicular lymphoma is associated with reduced intratumoral immune infiltration","volume":"37","author":"Tobin","year":"2019","journal-title":"J Clin Oncol"},{"issue":"7","key":"2025102809114897500_bib2","doi-asserted-by":"crossref","first-page":"1820","DOI":"10.1158\/1078-0432.CCR-16-1576","article-title":"The T-cell receptor repertoire influences the tumor microenvironment and is associated with survival in aggressive B-cell lymphoma","volume":"23","author":"Keane","year":"2017","journal-title":"Clin Cancer Res"},{"issue":"10","key":"2025102809114897500_bib3","doi-asserted-by":"crossref","first-page":"16,824","DOI":"10.1002\/jcp.28358","article-title":"PD-1\/PD-L1 pathway: basic biology and role in cancer immunotherapy","volume":"234","author":"Salmaninejad","year":"2019","journal-title":"J Cell Physiol"},{"key":"2025102809114897500_bib4","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1016\/j.ctrv.2017.11.008","article-title":"Rationale for combination of therapeutic antibodies targeting tumor cells and immune checkpoint receptors: harnessing innate and adaptive immunity through IgG1 isotype immune effector stimulation","volume":"63","author":"Ferris","year":"2018","journal-title":"Cancer Treat Rev"},{"issue":"1","key":"2025102809114897500_bib5","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1186\/s13045-022-01242-2","article-title":"Improvement of the anticancer efficacy of PD-1\/PD-L1 blockade via combination therapy and PD-L1 regulation","volume":"15","author":"Wu","year":"2022","journal-title":"J Hematol Oncol"},{"key":"2025102809114897500_bib6","doi-asserted-by":"crossref","first-page":"101,636","DOI":"10.1016\/j.tranon.2023.101636","article-title":"A systematic review and meta-analysis of immune checkpoint therapy in relapsed or refractory non-Hodgkin lymphoma; a friend or foe?","volume":"30","author":"Davoodi-Moghaddam","year":"2023","journal-title":"Transl Oncol"},{"issue":"21","key":"2025102809114897500_bib7","doi-asserted-by":"crossref","first-page":"8151","DOI":"10.3390\/ijms21218151","article-title":"Immunomodulatory effects of radiotherapy","volume":"21","author":"Kumari","year":"2020","journal-title":"Int J Mol Sci"},{"issue":"4","key":"2025102809114897500_bib8","doi-asserted-by":"crossref","first-page":"457","DOI":"10.1016\/S1470-2045(14)70036-1","article-title":"4 Gy versus 24 Gy radiotherapy for patients with indolent lymphoma (FORT): a randomised phase 3 non-inferiority trial","volume":"15","author":"Hoskin","year":"2014","journal-title":"Lancet Oncol"},{"issue":"7","key":"2025102809114897500_bib9","doi-asserted-by":"crossref","first-page":"1720","DOI":"10.1038\/s41375-022-01620-2","article-title":"The 5th edition of the World Health Organization classification of haematolymphoid tumours: lymphoid neoplasms","volume":"36","author":"Alaggio","year":"2022","journal-title":"Leukemia"},{"key":"2025102809114897500_bib10","doi-asserted-by":"crossref","first-page":"103,208","DOI":"10.1016\/j.jbi.2019.103208","article-title":"The REDCap consortium: building an international community of software platform partners","volume":"95","author":"Harris","year":"2019","journal-title":"J Biomed Inform"},{"issue":"2","key":"2025102809114897500_bib11","doi-asserted-by":"crossref","first-page":"e203","DOI":"10.1016\/j.prro.2020.11.003","article-title":"Efficacy of palliative radiation therapy (RT) for chemotherapy relapsed or refractory diffuse large B-cell lymphoma: a population-based retrospective review","volume":"11","author":"Wong","year":"2021","journal-title":"Pract Radiat Oncol"},{"issue":"3","key":"2025102809114897500_bib12","doi-asserted-by":"crossref","first-page":"332","DOI":"10.1016\/S1470-2045(20)30686-0","article-title":"4 Gy versus 24 Gy radiotherapy for follicular and marginal zone lymphoma (FoRT): long-term follow-up of a multicentre, randomised, phase 3, non-inferiority trial","volume":"22","author":"Hoskin","year":"2021","journal-title":"Lancet Oncol"},{"issue":"6","key":"2025102809114897500_bib13","doi-asserted-by":"crossref","first-page":"755","DOI":"10.2967\/jnumed.120.258152","article-title":"The Australasian Radiopharmaceutical Trials Network: clinical trials, evidence, and opportunity","volume":"62","author":"Francis","year":"2021","journal-title":"J Nucl Med"},{"issue":"27","key":"2025102809114897500_bib14","doi-asserted-by":"crossref","first-page":"3059","DOI":"10.1200\/JCO.2013.54.8800","article-title":"Recommendations for initial evaluation, staging, and response assessment of Hodgkin and non-Hodgkin lymphoma: the Lugano classification","volume":"32","author":"Cheson","year":"2014","journal-title":"J Clin Oncol"},{"issue":"5","key":"2025102809114897500_bib15","first-page":"720","article-title":"CD8-targeted PET imaging of tumor-infiltrating T cells in patients with cancer: a phase I first-in-humans study of 89Zr-Df-IAB22M2C, a radiolabeled anti-CD8 minibody","volume":"63","author":"Farwell","year":"2022","journal-title":"J Nucl Med"},{"issue":"1","key":"2025102809114897500_bib16","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1182\/blood-2003-05-1545","article-title":"Confirmation of the molecular classification of diffuse large B-cell lymphoma by immunohistochemistry using a tissue microarray","volume":"103","author":"Hans","year":"2004","journal-title":"Blood"},{"issue":"8","key":"2025102809114897500_bib17","doi-asserted-by":"crossref","first-page":"1214","DOI":"10.1182\/blood-2013-11-536433","article-title":"Determining cell-of-origin subtypes of diffuse large B-cell lymphoma using gene expression in formalin-fixed paraffin-embedded tissue","volume":"123","author":"Scott","year":"2014","journal-title":"Blood"},{"issue":"10","key":"2025102809114897500_bib18","doi-asserted-by":"crossref","first-page":"e445","DOI":"10.1016\/S2352-3026(15)00150-7","article-title":"Ratios of T-cell immune effectors and checkpoint molecules as prognostic biomarkers in diffuse large B-cell lymphoma: a population-based study","volume":"2","author":"Keane","year":"2015","journal-title":"Lancet Haematol"},{"key":"2025102809114897500_bib19","doi-asserted-by":"publisher","DOI":"10.1101\/2024.01.17.576100","article-title":"Integrative genomic analysis identifies unique immune environments associated with immunotherapy response in diffuse large B cell lymphoma","author":"Tumuluru","year":"5  2024","journal-title":"bioRxiv"},{"issue":"4","key":"2025102809114897500_bib29","doi-asserted-by":"crossref","DOI":"10.1016\/j.cell.2018.10.038","article-title":"Defining T cell states associated with response to checkpoint immunotherapy in melanoma","volume":"175","author":"Sade-Feldman","year":"2018","journal-title":"Cell"},{"issue":"282","key":"2025102809114897500_bib20","doi-asserted-by":"crossref","first-page":"457","DOI":"10.1080\/01621459.1958.10501452","article-title":"Nonparametric-estimation from incomplete observations","volume":"53","author":"Kaplan","year":"1958","journal-title":"J Am Stat Assoc"},{"issue":"260","key":"2025102809114897500_bib21","doi-asserted-by":"crossref","first-page":"583","DOI":"10.1080\/01621459.1952.10483441","article-title":"Use of ranks in one-criterion variance analysis","volume":"47","author":"Kruskal","year":"1952","journal-title":"J Am Stat Assoc"},{"issue":"2","key":"2025102809114897500_bib22","doi-asserted-by":"crossref","first-page":"99","DOI":"10.2307\/3001913","article-title":"Comparing individual means in the analysis of variance","volume":"5","author":"Tukey","year":"1949","journal-title":"Biometrics"},{"issue":"1","key":"2025102809114897500_bib23","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1214\/aoms\/1177730491","article-title":"On a test of whether one of two random variables is stochastically larger than the other","volume":"18","author":"Mann","year":"1947","journal-title":"Ann Math Statist"},{"issue":"3","key":"2025102809114897500_bib24","doi-asserted-by":"crossref","first-page":"238","DOI":"10.1016\/j.clbc.2020.01.012","article-title":"A phase II study of pembrolizumab in combination with palliative radiotherapy for hormone receptor-positive metastatic breast cancer","volume":"20","author":"Barroso-Sousa","year":"2020","journal-title":"Clin Breast Cancer"},{"issue":"suppl 16","key":"2025102809114897500_bib25","doi-asserted-by":"crossref","first-page":"TPS7092","DOI":"10.1200\/JCO.2024.42.16_suppl.TPS7092","article-title":"First-line treatment of follicular lymphoma (FL) with golcadomide, rituximab +\/- nivolumab: an umbrella randomised phase 2 investigator-led study","volume":"42","author":"Chong","year":"2024","journal-title":"J Clin Oncol"},{"issue":"suppl 4","key":"2025102809114897500_bib26","doi-asserted-by":"crossref","first-page":"375","DOI":"10.1200\/JCO.2024.42.4_suppl.375","article-title":"Baseline CD8 lymph node avidity with 89-Zr-crefmirlimab in patients with metastatic renal cell carcinoma and response to IO therapy","volume":"42","author":"Zang","year":"2024","journal-title":"J Clin Oncol"},{"issue":"4","key":"2025102809114897500_bib27","doi-asserted-by":"crossref","first-page":"218","DOI":"10.1038\/s41568-019-0235-4","article-title":"CD8+ T cell states in human cancer: insights from single-cell analysis","volume":"20","author":"van der Leun","year":"2020","journal-title":"Nat Rev Cancer"},{"issue":"4","key":"2025102809114897500_bib28","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1038\/s41577-021-00574-3","article-title":"CD8+ T cell differentiation and dysfunction in cancer","volume":"22","author":"Philip","year":"2022","journal-title":"Nat Rev Immunol"}],"container-title":["Blood Advances"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/ashpublications.org\/bloodadvances\/article-pdf\/9\/20\/5263\/2417074\/blooda_adv-2025-016505-main.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/ashpublications.org\/bloodadvances\/article-pdf\/9\/20\/5263\/2417074\/blooda_adv-2025-016505-main.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,28]],"date-time":"2025-10-28T13:12:10Z","timestamp":1761657130000},"score":1,"resource":{"primary":{"URL":"https:\/\/ashpublications.org\/bloodadvances\/article\/9\/20\/5263\/537883\/T-cell-dysregulation-informs-radiotherapy"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,10,17]]},"references-count":29,"journal-issue":{"issue":"20","published-print":{"date-parts":[[2025,10,28]]}},"URL":"https:\/\/doi.org\/10.1182\/bloodadvances.2025016505","relation":{},"ISSN":["2473-9529","2473-9537"],"issn-type":[{"value":"2473-9529","type":"print"},{"value":"2473-9537","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2025,10,28]]},"published":{"date-parts":[[2025,10,17]]}}}